A Massachusetts-based wound care and sports medicine company announced plans recently for a new biomanufacturing facility in Smithfield. Regenerative medicine company Organogenesis is investing roughly $100 million to build the facility off Technology Way, with plans to add more than 200 full-time jobs.
The 122,000 square-foot site will house manufacturing, laboratory, warehouse, and distribution operations to support the company’s “advanced wound care” products, including future expansions. It will also be equipped to resume production of Dermagraft, an FDA-approved product used to treat diabetic foot ulcers, according to Organogenesis.
CEO and Board Chair Gary S. Gillheeney Sr. called the project a vital aspect of the company’s commitment to growing its presence in New England. He said their vision for the facility is to “be a catalyst” for the life sciences industry in Rhode Island and to foster “continued regional cooperation in biotechnology.”…